Use of Anti-Prolactin Agents to Treat Cancer/Proliferative Conditions
US 7,115,556 Canada 2,328,520 Japan 5,453,355 Japan 5,259,896
Use of Prolactin Receptor Antagonists in Combination with an Agent that Inactivates the HER2/Neu signaling Pathway
US 8,754,031
Compositions and Methods for Visualizing and Eliminating Cancer Stem Cells (Ovarian Cancer Claims)
US 8,648,046 US 8,754,035 Europe 2400979 France 2400979 Germany 2400979 Italy 2400979 United Kingdom 2400979 Australia 2010218261 Japan 5963443 Korea 10-1672401
Human Prolactin Antagonist-Angiogenesis Inhibitor Fusion Proteins
US 7,339,027 US 8,304, 381 Japan 4511108 Japan 5221510
Multimeric Ligands with Enhanced Stability
US 7,632,809 Canada 2,483,330 Europe 2385132 France 2385132 Germany 60345826.2 United Kingdom 2385132 Europe 1576097 France 1576097 Germany 60342479.1 United Kingdom 1576097
Use of Prolactin in the Prophylactic Treatment of Cancer
Europe 1959985 France 1959985 Germany 602006009840.5 United Kingdom 1579985
Bi-Functional Cancer Treatment Agents
US 7,201,905
In addition to patents, Prolanta has received orphan designation from the US FDA for the treatment of ovarian cancer, which provides for seven years of market exclusivity. Oncolix intends to apply for orphan designation in the EU and Japan to treat ovarian cancer, both which provide for 10 years of market exclusivity.
Furthermore, under the US Affordable Care Act in the United States, biologicals such as Prolanta are granted 12 years of market exclusivity.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.